November 1, 2025International Journal of General MedicineOpen Access

Quantitative Evaluation of Cardiac Function Improvement by Conventional Cardiology Drug Regimens Combined with Sacubitril/Valsartan Sodium in Heart Failure Patients

View Full Paper

Ask AI

Bookmark

Why the study?

To explore the effect of conventional cardiology drug therapy combined with sacubitril/valsartan sodium on improving cardiac function in patients with heart failure.

Does sacubitril/valsartan added to conventional therapy improve cardiac function and clinical outcomes in patients with heart failure?

Structured PICO

Does sacubitril/valsartan added to conventional therapy improve cardiac function and clinical outcomes in patients with heart failure?

Population

Heart failure patients diagnosed and treated in a single hospital between March 2022 and December 2023

Intervention

Sacubitril/valsartan added to conventional cardiology drug therapy

Comparator

Conventional cardiology drug therapy alone

Outcome

Overall clinical efficacy rate and cardiac function indicatorssurrogate

Adding sacubitril/valsartan to conventional therapy in heart failure patients significantly improves cardiac function, neuroendocrine profiles, and quality of life without increasing adverse events.

Implication

Should not yet change practice; leaves open confirmation in prospective randomized heart failure trials.

Abstract

Objective: To explore the effect of conventional cardiology drug therapy combined with sacubitril/valsartan sodium on improving cardiac function in patients with heart failure. Methods: A retrospective analysis was conducted on data from heart failure patients diagnosed and treated in our hospital between March 2022 and December 2023. Patients were divided into a control group and an experimental group based on treatment methods. The control group received conventional cardiology drug therapy, while the experimental group received conventional cardiology drug therapy combined with sacubitril/valsartan sodium. Cardiac function indicators and related clinical outcomes were compared between the two groups before and after treatment. Results: The overall clinical efficacy rate in the experimental group was significantly higher than in the control group (P < 0.05). After treatment, the experimental group exhibited higher levels of LVEF, SV, and CO, while LVESD and LVEDD levels were significantly lower compared to the control group (P < 0.05). Levels of NT-proBNP, Hcy, and cTnI in the experimental group were significantly lower than in the control group after treatment (P < 0.05). Additionally, levels of NE, ALD, and AngII in the experimental group were significantly lower than those in the control group post-treatment (P < 0.05). The 6-minute walk test (6 MWT) performance was better in the experimental group, and their MLHFQ (Minnesota Living with Heart Failure Questionnaire) scores were lower than those in the control group (P < 0.05). The incidence of adverse events was similar between the two groups (P > 0.05). Conclusion: Conventional cardiology drug therapy combined with sacubitril/valsartan sodium significantly improves cardiac function in patients with heart failure. It achieves this by modulating neuroendocrine function, counteracting adverse effects, and promoting the reversal of ventricular remodeling. The treatment also demonstrates good safety, effectively enhancing patients' exercise capacity and quality of life.